Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925939 | 1.00 | HTR2A (0.65) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL2924439 | 1.00 | HTR2A (0.65) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL21254603 | 0.91 | HTR2A (0.59) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL31381402 | 0.89 | CYP3A4 (0.60) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL26668483 | 0.89 | CYP3A4 (0.60) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL26668476 | 0.89 | CYP3A4 (0.60) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL15287592 | 0.87 | SLC6A4 (0.55) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL15284978 | 0.87 | SLC6A4 (0.55) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL3195707 | 0.86 | SLC6A4 (0.71) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 | |
| SCHEMBL3195689 | 0.86 | SLC6A4 (0.71) | HTR2ASLC6A4SLC6A2HTR2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| CN-104352492-B | Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient | MSD K.K.公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2015128698-A1 | SUBSTITUTED HETEROCYCLIC AMINE DERIVATIVES AS MULTIKINASE INHIBITORS FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2015-09-03 | — | — | WO | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| EP-1248521-B1 | PEST CONTROL AGENTS / DEPSIPEPTIDES | BAYER CROPSCIENCE AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030143254-A1 | Pest control agents/depsipeptides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
| EP-1248521-A1 | PEST CONTROL AGENTS / DEPSIPEPTIDES | Bayer Aktiengesellschaft (DE) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001045512-A1 | PEST CONTROL AGENTS / DEPSIPEPTIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
| US-5614518-A | Morpholine derivatives as dopamine receptor subtype ligands | MERCK SHARP & DOHME LTD. (GB) | 1997-03-25 | — | — | US | disclosed |
| EP-0730593-A1 | MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014690-A1 | MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1995-06-01 | — | — | WO | disclosed |
| US-3806595-A | METHOD OF PRODUCING ANOREXIA | ICI LTD | 1974-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | HTR2A 4528/4885SLC6A4 4641/4885SLC6A2 4635/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | HTR2A 4081/4885SLC6A4 3854/4885SLC6A2 3863/4885 |
| US-20030143254-A1 | Pest control agents/depsipeptides | CTRL, RRP12, VIP | HTR2A 4303/4885SLC6A4 4872/4885SLC6A2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.